Format

Send to

Choose Destination
Cancer. 2017 Nov 1;123(21):4224-4235. doi: 10.1002/cncr.30873. Epub 2017 Jul 11.

Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.

Author information

1
Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts.
2
Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, Ohio.
3
Department of Pathology, The Ohio State University College of Medicine, Columbus, Ohio.
4
Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio.
5
Children's Oncology Group Statistics and Data Center, University of Florida, Gainesville, Florida.
6
Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
7
Department of Pediatrics, University of California at San Francisco Benioff Children's Hospital, University of California at San Francisco School of Medicine, San Francisco, California.
8
Department of Pediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada.
9
Department of Pathology, Children's Hospital of Los Angeles, Los Angeles, California.
10
Department of Hematology/Oncology, Cook Children's Hospital, Fort Worth, Texas.
11
Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, Washington.

Abstract

BACKGROUND:

High-level MYCN amplification (MNA) is associated with poor outcome and unfavorable clinical and biological features in patients with neuroblastoma. To the authors' knowledge, less is known regarding these associations in patients with low-level MYCN copy number increases.

METHODS:

In this retrospective study, the authors classified patients has having tumors with MYCN wild-type tumors, MYCN gain (2-4-fold increase in MYCN signal compared with the reference probe), or MNA (>4-fold increase). Tests of trend were used to investigate ordered associations between MYCN copy number category and features of interest. Log-rank tests and Cox models compared event-free survival and overall survival by subgroup.

RESULTS:

Among 4672 patients, 3694 (79.1%) had MYCN wild-type tumors, 133 (2.8%) had MYCN gain, and 845 (18.1%) had MNA. For each clinical/biological feature, the percentage of patients with an unfavorable feature was lowest in the MYCN wild-type category, intermediate in the MYCN gain category, and highest in the MNA category (P<.0001), except for 11q aberration, for which the highest rates were in the MYCN gain category. Patients with MYCN gain had inferior event-free survival and overall survival compared with those with MYCN wild-type. Among patients with high-risk disease, MYCN gain was associated with the lowest response rate after chemotherapy. Patients with non-stage 4 disease (according to the International Neuroblastoma Staging System) and patients with non-high-risk disease with MYCN gain had a significantly increased risk for death, a finding confirmed on multivariable testing.

CONCLUSIONS:

Increasing MYCN copy number is associated with an increasingly higher rate of unfavorable clinical/biological features, with 11q aberration being an exception. Patients with MYCN gain appear to have inferior outcomes, especially in otherwise more favorable groups. Cancer 2017;123:4224-4235. © 2017 American Cancer Society.

KEYWORDS:

MYCN; amplification; gain; neuroblastoma; ploidy; prognosis; segmental chromosomal aberration

PMID:
28696504
PMCID:
PMC5650521
DOI:
10.1002/cncr.30873
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center